Cargando…
Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review
We report the case of a 71-year-old Japanese woman with adult-onset Still's disease (AOSD) in whom macrophage activation syndrome (MAS) developed despite therapy with oral high-dose prednisolone and intravenous methylprednisolone pulse therapy twice. She was successfully treated with tocilizuma...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027298/ https://www.ncbi.nlm.nih.gov/pubmed/27688774 http://dx.doi.org/10.1155/2016/5656320 |
_version_ | 1782454216987508736 |
---|---|
author | Watanabe, Eri Sugawara, Hitoshi Yamashita, Takeshi Ishii, Akira Oda, Aya Terai, Chihiro |
author_facet | Watanabe, Eri Sugawara, Hitoshi Yamashita, Takeshi Ishii, Akira Oda, Aya Terai, Chihiro |
author_sort | Watanabe, Eri |
collection | PubMed |
description | We report the case of a 71-year-old Japanese woman with adult-onset Still's disease (AOSD) in whom macrophage activation syndrome (MAS) developed despite therapy with oral high-dose prednisolone and intravenous methylprednisolone pulse therapy twice. She was successfully treated with tocilizumab (TCZ). Soon afterward, her fever ceased and high levels of both ferritin and C-reactive protein levels decreased. Her course was complicated by disseminated intravascular coagulation, cytomegalovirus infection, and Pneumocystis jirovecii pneumonia. After these were resolved, AOSD-associated MAS was well controlled. She was discharged on hospital day 87. Although biologics such as TCZ are becoming established for the treatment of AOSD, there is no recommended therapy for AOSD-associated MAS. Several biologics have been tried for this complication, but their efficacy and safety remain controversial. We reviewed reported cases of AOSD-associated MAS successfully treated with various biologics. TCZ initiation after adequate nonselective immunosuppressive therapy, such as methylprednisolone pulse therapy or a prednisolone-based combination of immunosuppressants, can be an effective treatment for AOSD-associated MAS. On the other hand, biologics given after insufficient immunosuppressive therapy may cause MAS. A strategy combining adequate immunosuppression and a biologic could be safe if special attention is given to adverse events such as opportunistic infections or biologic-associated MAS. |
format | Online Article Text |
id | pubmed-5027298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-50272982016-09-29 Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review Watanabe, Eri Sugawara, Hitoshi Yamashita, Takeshi Ishii, Akira Oda, Aya Terai, Chihiro Case Rep Med Case Report We report the case of a 71-year-old Japanese woman with adult-onset Still's disease (AOSD) in whom macrophage activation syndrome (MAS) developed despite therapy with oral high-dose prednisolone and intravenous methylprednisolone pulse therapy twice. She was successfully treated with tocilizumab (TCZ). Soon afterward, her fever ceased and high levels of both ferritin and C-reactive protein levels decreased. Her course was complicated by disseminated intravascular coagulation, cytomegalovirus infection, and Pneumocystis jirovecii pneumonia. After these were resolved, AOSD-associated MAS was well controlled. She was discharged on hospital day 87. Although biologics such as TCZ are becoming established for the treatment of AOSD, there is no recommended therapy for AOSD-associated MAS. Several biologics have been tried for this complication, but their efficacy and safety remain controversial. We reviewed reported cases of AOSD-associated MAS successfully treated with various biologics. TCZ initiation after adequate nonselective immunosuppressive therapy, such as methylprednisolone pulse therapy or a prednisolone-based combination of immunosuppressants, can be an effective treatment for AOSD-associated MAS. On the other hand, biologics given after insufficient immunosuppressive therapy may cause MAS. A strategy combining adequate immunosuppression and a biologic could be safe if special attention is given to adverse events such as opportunistic infections or biologic-associated MAS. Hindawi Publishing Corporation 2016 2016-09-05 /pmc/articles/PMC5027298/ /pubmed/27688774 http://dx.doi.org/10.1155/2016/5656320 Text en Copyright © 2016 Eri Watanabe et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Watanabe, Eri Sugawara, Hitoshi Yamashita, Takeshi Ishii, Akira Oda, Aya Terai, Chihiro Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review |
title | Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review |
title_full | Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review |
title_fullStr | Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review |
title_full_unstemmed | Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review |
title_short | Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review |
title_sort | successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset still's disease: a case-based review |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027298/ https://www.ncbi.nlm.nih.gov/pubmed/27688774 http://dx.doi.org/10.1155/2016/5656320 |
work_keys_str_mv | AT watanabeeri successfultocilizumabtherapyformacrophageactivationsyndromeassociatedwithadultonsetstillsdiseaseacasebasedreview AT sugawarahitoshi successfultocilizumabtherapyformacrophageactivationsyndromeassociatedwithadultonsetstillsdiseaseacasebasedreview AT yamashitatakeshi successfultocilizumabtherapyformacrophageactivationsyndromeassociatedwithadultonsetstillsdiseaseacasebasedreview AT ishiiakira successfultocilizumabtherapyformacrophageactivationsyndromeassociatedwithadultonsetstillsdiseaseacasebasedreview AT odaaya successfultocilizumabtherapyformacrophageactivationsyndromeassociatedwithadultonsetstillsdiseaseacasebasedreview AT teraichihiro successfultocilizumabtherapyformacrophageactivationsyndromeassociatedwithadultonsetstillsdiseaseacasebasedreview |